Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer

Cancer Letters

Volumn 347, Issue 2, 2014, Pages 204-211

  Roper, Jatin ^a   Sinnamon, Mark J ^b   Coffee, Erin M ^c   Belmont, Peter ^d   Keung, Lily ^a   Georgeon Richard, Larissa ^a   Wang, Wei Vivian ^a   Faber, Anthony C ^c   Yun, Jihye ^e   Yilmaz, Ömer H ^f   Bronson, Roderick T ^g   Martin, Eric S ^g   Tsichlis, Philip N ^a   Hung, Kenneth E ^h  

^a TUFTS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d Oncology Research   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h PFIZER INC   (United States)

Author keywords

Colorectal cancer; KRAS; MEK; Mouse model of cancer; PI3K

Indexed keywords

COLORECTAL CANCER; KRAS; MEK; MOUSE MODEL OF CANCER; PI3K;

ANIMALS; APOPTOSIS; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; GENES, RAS; HUMANS; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C57BL; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84898462986     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.02.018     Document Type: Article

References (50)

1. Bos J.L., Fearon E.R., Hamilton S.R., Verlaan-de Vries M., van Boom J.H., van der Eb A.J., et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987, 327:293-297.
2. Castellano E., Downward J. RAS interaction with PI3K. Genes Cancer 2011, 2:261-274.
3. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
4. Seshagiri S., Stawiski E.W., Durinck S., Modrusan Z., Storm E.E., Conboy C.B., et al. Recurrent R-spondin fusions in colon cancer. Nature 2012, 488:660-664.
5. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
6. Imielinski M., Berger A.H., Hammerman P.S., Hernandez B., Pugh T.J., Hodis E., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120.
7. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
8. Tada M., Omata M., Ohto M. Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology 1991, 100:233-238.
9. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359:1757-1765.
10. Ludovini V., Bianconi F., Pistola L., Pistola V., Chiari R., Colella R., et al. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother. Pharmacol. 2012, 69:1289-1299.
11. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
12. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
13. Weiss G.A., Rossi M.R., Khushalani N.I., Lo K., Gibbs J.F., Bharthuar A., et al. Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma. J. Gastrointest. Oncol. 2013, 4:20-29.
14. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11:753-762.
15. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
16. Shirasawa S., Furuse M., Yokoyama N., Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993, 260:85-88.
17. Maira S.-M., Pecchi S., Huang A., Burger M., Knapp M., Sterker D., et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol. Cancer Ther. 2012, 11:317-328.
18. Ciuffreda L., Del Bufalo D., Desideri M., Di Sanza C., Stoppacciaro A., Ricciardi M.R., et al. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 2009, 11:720-731.
19. Martin E.S., Belmont P.J., Sinnamon M.J., Richard L.G., Yuan J., Coffee E.M., et al. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin. Cancer Res. 2013, 19:2929-2940.
20. Hung K.E., Maricevich M.A., Richard L.G., Chen W.Y., Richardson M.P., Kunin A., et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc. Natl. Acad. Sci. USA 2010, 107:1565-1570.
21. Roper J., Richardson M.P., Wang W.V., Richard L.G., Chen W., Coffee E.M., et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS ONE 2011, 6:e25132.
22. Neurath M.F., Wittkopf N., Wlodarski A., Waldner M., Neufert C., Wirtz S., et al. Assessment of tumor development and wound healing using endoscopic techniques in mice. Gastroenterology 2010, 139:1837-1843.e1.
23. Gargalionis A.N., Karamouzis M.V., Papavassiliou A.G. The molecular rationale of Src inhibition in colorectal carcinomas. Int. J. Cancer 2014, 134:2019-2029.
24. Fujishita T., Aoki K., Lane H.A., Aoki M., Taketo M.M. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc. Natl. Acad. Sci. USA 2008, 105:13544-13549.
25. Fujishita T., Aoki M., Taketo M.M. JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in Apc(δ716) mice. Gastroenterology 2011, 140:1556-1563.e6.
26. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
27. Perciavalle R.M., Opferman J.T. Delving deeper: MCL-1's contributions to normal and cancer biology. Trends Cell Biol. 2013, 23:22-29.
28. Singh A., Sweeney M.F., Yu M., Burger A., Greninger P., Benes C., et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 2012, 148:639-650.
29. Scholl C., Fröhling S., Dunn I.F., Schinzel A.C., Barbie D.A., Kim S.Y., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834.
30. Barbie D.A., Tamayo P., Boehm J.S., Kim S.Y., Moody S.E., Dunn I.F., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
31. Vicent S., Chen R., Sayles L.C., Lin C., Walker R.G., Gillespie A.K., et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J. Clin. Invest. 2010, 120:3940-3952.
32. Kumar M.S., Hancock D.C., Molina-Arcas M., Steckel M., East P., Diefenbacher M., et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 2012, 149:642-655.
33. Corcoran R.B., Cheng K.A., Hata A.N., Faber A.C., Ebi H., Coffee E.M., et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013, 23:121-128.
34. Babij C., Zhang Y., Kurzeja R.J., Munzli A., Shehabeldin A., Fernando M., et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res. 2011, 71:5818-5826.
35. Britten C.D. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother. Pharmacol. 2013, 71:1395-1409.
36. Yu K., Toral-Barza L., Shi C., Zhang W.-G., Zask A. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol. Ther. 2008, 7:307-315.
37. Wee S., Jagani Z., Xiang K.X., Loo A., Dorsch M., Yao Y.-M., et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009, 69:4286-4293.
38. Halilovic E., She Q.-B., Ye Q., Pagliarini R., Sellers W.R., Solit D.B., et al. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res. 2010, 70:6804-6814.
39. Migliardi G., Sassi F., Torti D., Galimi F., Zanella E.R., Buscarino M., et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin. Cancer Res. 2012, 18:2515-2525.
40. Kinross K.M., Brown D.V., Kleinschmidt M., Jackson S., Christensen J., Cullinane C., et al. In vivo activity of combined PI3K/mTOR and MEK inhibition in a KrasG12D;Pten deletion mouse model of ovarian cancer. Mol. Cancer Ther. 2011, 10:1440-1449.
41. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
42. Martinelli E., Troiani T., D'Aiuto E., Morgillo F., Vitagliano D., Capasso A., et al. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int. J. Cancer 2013, 133:2089-2101.
43. Janku F., Tsimberidou A.M., Garrido-Laguna I., Wang X., Luthra R., Hong D.S., et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol. Cancer Ther. 2011, 10:558-565.
44. Coffee E.M., Faber A.C., Roper J., Sinnamon M.J., Goel G., Keung L., et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAFV600E colorectal cancer. Clin. Cancer Res. 2013, 19:2688-2698.
45. Corcoran R.B., Rothenberg S.M., Hata A.N., Faber A.C., Piris A., Nazarian R.M., et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci. Transl. Med. 2013, 5. 196ra98-196ra98.
46. Elkabets M., Vora S., Juric D., Morse N., Mino-Kenudson M., Muranen T., et al. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med. 2013, 5:196ra99.
47. Bean G.R., Ganesan Y.T., Dong Y., Takeda S., Liu H., Chan P.M., et al. PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci. Signal. 2013, 6:ra20.
48. Paraiso K.H.T., Haarberg H.E., Wood E., Rebecca V.W., Chen Y.A., Xiang Y., et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin. Cancer Res. 2012, 18:2502-2514.
49. Faber A.C., Ebi H., Costa C., Engelman J.A. Apoptosis in targeted therapy responses: the role of BIM. Adv. Pharmacol. 2012, 65:519-542.
50. Faber A.C., Coffee E.M., Costa C., Dastur A., Ebi H., Hata A.N., et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov. 2014, 4:42-52.